Under the terms of the three-year, renewable agreement with EKR, ProStrakan will receive undisclosed payments based on the volume of packs of Gelclair that are sold in the US from May 2009.
ProStrakan said that it will offer Gelclair as a second detail to oncologists and oncology nurses across the US through its 75-strong US sales force, which is already promoting Sancuso.
Gelclair was approved by the FDA in late 2001 and EKR obtained North American rights to the product in 2006 from Helsinn Healthcare of Switzerland.
ProStrakan plans to market this oncology support product alongside Sancuso, its transdermal patch for the prevention of chemotherapy-induced nausea and vomiting in patients receiving chemotherapy for up to five consecutive days. Sancuso received approval from the FDA in September 2008.
Wilson Totten, ProStrakan’s CEO, said: “Gelclair and Sancuso are highly complementary. The addition of Gelclair to our US product range presents ProStrakan with an excellent opportunity to capitalize on the access that Sancuso has created for our team to oncologists and oncology nurses across the US. We hope that in this way we can help to improve the quality of life for more chemotherapy patients.”